Skip to main content

Rivaroxaban Comparable to Warfarin in Preventing Stroke and Other Complications of AF

News

Rivaroxaban Comparable to Warfarin in Preventing Stroke and Other Complications of AF

11/18/2010

CHICAGO, Nov. 15, 2010 – An anticoagulant is as effective as the standard medication in preventing stroke and blood clots and does not increase bleeding risk among patients with the most common form of atrial fibrillation (AF), according to late-breaking randomized, double-blind clinical trial results presented at the American Heart Association’s Scientific Sessions 2010. In Stroke Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared With Warfarin in Patients with Nonvalvular Atrial Fibrillation (ROCKET AF), investigators compared the new drug rivaroxaban with the traditional medicine warfarin in 14,264 patients with AF that was not related to heart valve disease. The median time that patients spent in the therapeutic range with warfarin during the course of the trial was 57.8%. Patients spent on average 11.9% of the time above the therapeutic range, while they were below this range 19.7% of the time. In the primary analysis, measuring what happened to research participants while they were actually taking the study drug, those taking rivaroxaban compared with warfarin had fewer strokes and blood emboli to other parts of the body. With rivaroxaban there were 1.71 events per 100 patient-years (188 patients) and with warfarin 2.16 (241 patients), p
Back to Top